22 research outputs found
Rapid and flexible scale-down media development and optimization for perfusion culture
Perfusion culture is steadily gaining interest due to advantages such as higher cell densities, increased flexibility, higher volumetric output, decreased product retention times, and more consistent product. Perfusion culture systems are drastically different than fed-batch cultures as they allow bioreactors to continuously run for prolonged periods of time by constantly feeding fresh media while removing spent media. This drastic process difference means that typical fed-batch medium is not optimal for perfusion culture. Instead, perfusion culture media is most optimal when it fits within culture process constraints such as vessel volume exchanges per day. Irvine Scientific has rapidly developed custom media for a specific perfusion culture process that resulted in a significant increase in viable cell density and antibody titer. The custom media was developed in the following steps: (1) identification of initial base media, (2) development and verification of a scale-down perfusion model, (3) optimization of media components, and (4) parsing down extraneous components while maintaining growth and titer. First, a media survey was conducted in batch cultures to determine an initial basal media composition to further refine. From a panel of over 20 different media, top candidate media were selected based on improved viable cell density, viability, titer, and glycan profile over the control medium. Next, a scale-down perfusion model was developed and validated using the control medium. Mini bioreactor tubes were used as culture vessels and daily perfusion was conducted by centrifugation, aspiration, and replenishment with fresh medium. Antibody glycan profiles from the scale-down perfusion model matched profiles from large-scale bioreactor perfusion cultures, thus validating the use of this scale-down model. Although this system is not controlled, the pH was monitored offline and stayed within range. The candidate media were evaluated in the scale-down perfusion model and the top prospects in terms of titer and viable cell density were chosen for further development by changing the composition of amino acids, metals, and other components. Lastly, amino acid concentrations were further optimized while parsing down extraneous components according to spent media analysis from the previous experiment. The top medium resulted in a significant increase in viable cell density and titer compared to the original control medium. This process created a custom medium for perfusion culture that significantly increased viable cell density and antibody titer while maintaining a desired glycan profile. The media development process in scale-down perfusion cultures was rapid and took about 10 weeks. Development in controlled, scale-down bioreactor systems may be more costly and take longer as procedures, protocols, and methods first need to be transferred and verified. This scale-down perfusion model, while manual, is an easy and flexible way to develop perfusion medium with efficient throughput. Currently, the medium is being verified in perfusion bioreactors and can be further improved. In the future, we will investigate increasing the productivity by concentrating the culture medium while decreasing the volume vessel exchanges
Development of an animal-component free insect medium for the Baculovirus Expression Vector System (BEVS)
Insect cells derived from Spodoptera frugiperda have been widely used with the baculovirus expression vector system (BEVS) for the production of recombinant proteins and adeno-associated viruses (AAVs) due to their ease of culture, scalability in high cell density suspension cultures, and high protein expression levels. Traditionally, insect cells are cultured in an undefined medium containing yeast hydrolysate and cod liver oil, however, there is an increasing push to use chemically defined, animal-component free medium to minimize any potential contaminants and decrease lot-to-lot variability while maintaining high cell growth and production. In this case study, an animal-component free insect medium was developed utilizing Rational Culture Media DesignTM and evaluated with Sf9 cells. Using a traditional formulation as a starting point, the final medium was developed by optimizing multiple nutrient groups in the basal medium, replacing the animal-derived components, and screening several yeast hydrolysate sources. By utilizing multifactor design of experiment software, various nutrient groups were screened including amino acids, vitamins, and metals. The metals group was identified to have the most impact on cell growth and productivity, and therefore concentrations of metal components were further optimized. In addition, the animal-derived components in the starting formulation, cod liver oil and cholesterol, were replaced with animal-component free fatty acids and synthetic cholesterol, respectively. The concentrations of these components were optimized to achieve better growth performance and production while also sustaining formulation stability and streamlining manufacturing processes. Finally, yeast hydrolysate is a well-known, undefined component that is crucial for insect cell growth and productivity. To minimize lot-to-lot variability, the yeast hydrolysate concentration was significantly lowered, and multiple yeast hydrolysate sources and lots were evaluated to determine the highest quality source. As a result, an animal-component free insect medium was developed that had improved growth performance and comparable productivity to a widely used commercially available animal-derived medium
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study
Introduction:
The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures.
Methods:
In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025.
Findings:
Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2–6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MRI were more frequent in patients than in controls (157 [61%] of 259 vs 14 [27%] of 52; p<0·0001) and independently associated with COVID-19 status (odds ratio [OR] 2·9 [95% CI 1·5–5·8]; padjusted=0·0023) after adjusting for relevant confounders. Compared with controls, patients were more likely to have MRI evidence of lung abnormalities (p=0·0001; parenchymal abnormalities), brain abnormalities (p<0·0001; more white matter hyperintensities and regional brain volume reduction), and kidney abnormalities (p=0·014; lower medullary T1 and loss of corticomedullary differentiation), whereas cardiac and liver MRI abnormalities were similar between patients and controls. Patients with multiorgan abnormalities were older (difference in mean age 7 years [95% CI 4–10]; mean age of 59·8 years [SD 11·7] with multiorgan abnormalities vs mean age of 52·8 years [11·9] without multiorgan abnormalities; p<0·0001), more likely to have three or more comorbidities (OR 2·47 [1·32–4·82]; padjusted=0·0059), and more likely to have a more severe acute infection (acute CRP >5mg/L, OR 3·55 [1·23–11·88]; padjusted=0·025) than those without multiorgan abnormalities. Presence of lung MRI abnormalities was associated with a two-fold higher risk of chest tightness, and multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment (PHOSP-COVID symptom clusters) after hospitalisation.
Interpretation:
After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeutic stratification
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two
Background
The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd.
Methods
We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background.
Results
First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001).
Conclusions
In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival
Generation of Two Noradrenergic-Specific Dopamine-Beta-Hydroxylase-FLPo Knock-In Mice Using CRISPR/Cas9-Mediated Targeting in Embryonic Stem Cells
Genetic association suggests that SMOC1 mediates between prenatal sex hormones and digit ratio
Men and women differ statistically in the relative lengths of their index and ring fingers; and the ratio of these lengths has been used as a biomarker for prenatal testosterone. The ratio has been correlated with a wide range of traits and conditions including prostate cancer, obesity, autism, ADHD, and sexual orientation. In a genome-wide association study of 979 healthy adults, we find that digit ratio is strongly associated with variation upstream of SMOC1 (rs4902759: P = 1.41 Ă— 10(-8)) and a meta-analysis of this and an independent study shows a probability of P = 1.5 Ă— 10(-11). The protein encoded by SMOC1 has recently been shown to play a critical role in limb development; its expression in prostate tissue is dependent on sex hormones, and it has been implicated in the sexually dimorphic development of the gonads. We put forward the hypothesis that SMOC1 provides a link between prenatal hormone exposure and digit ratio
Native Chemical Ligation of Thioamide-Containing Peptides: Development and Application to the Synthesis of Labeled α-Synuclein for Misfolding Studies
Factors influencing success of clinical genome sequencing across a broad spectrum of disorders
To assess factors influencing the success of whole-genome sequencing for mainstream clinical diagnosis, we sequenced 217 individuals from 156 independent cases or families across a broad spectrum of disorders in whom previous screening had identified no pathogenic variants. We quantified the number of candidate variants identified using different strategies for variant calling, filtering, annotation and prioritization. We found that jointly calling variants across samples, filtering against both local and external databases, deploying multiple annotation tools and using familial transmission above biological plausibility contributed to accuracy. Overall, we identified disease-causing variants in 21% of cases, with the proportion increasing to 34% (23/68) for mendelian disorders and 57% (8/14) in family trios. We also discovered 32 potentially clinically actionable variants in 18 genes unrelated to the referral disorder, although only 4 were ultimately considered reportable. Our results demonstrate the value of genome sequencing for routine clinical diagnosis but also highlight many outstanding challenges